Reuters logo
BRIEF-Incyte says Jakafi Phase 3 results show survival benefit in MF patients
2016年6月6日 / 中午11点52分 / 1 年前

BRIEF-Incyte says Jakafi Phase 3 results show survival benefit in MF patients

June 6 (Reuters) - Incyte Corp :

* COMFORT-I data demonstrate that treatment with Jakafi resulted in a 31 percent reduction in risk of death

* COMFORT-I data demonstrate sustained durable spleen volume reduction in patients with MF

* Overall, 69 (45%) and 82 (53%) deaths were reported in Ruxolitinib and placebo arms, respectively

* Median OS has not been reached for patients randomized to receive Ruxolitinib

* There was no increase in incidence of adverse events with longer exposure to treatment

* Five-Year results from phase 3 study of Jakafi (ruxolitinib) show sustained overall survival benefit in patients with myelofibrosis (MF) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below